Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 6/20 | 0.61 |
| ▸ | VIPR1 | P32241 | 5/20 | 0.59 |
| ▸ | VIPR2 | P41587 | 7/20 | 0.56 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.55 |
| ▸ | CDK2 | P24941 | 2/20 | 0.55 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.55 |
| ▸ | PTH1R | Q03431 | 2/20 | 0.55 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.54 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.54 |
| ▸ | CCKBR | P32239 | 1/20 | 0.54 |
| ▸ | GLP1R | P43220 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Styelin A SCHEMBL29386602 | 0.85 | IL23R (0.56) | OPRL1VIPR1VIPR2PTH1R | |
| SCHEMBL29464255 | 0.85 | PTH1R (0.55) | OPRL1CCNA2CDK2CCNA1PTH1R | |
| SCHEMBL29352003 | 0.84 | CCNA2 (0.57) | OPRL1VIPR1VIPR2CCNA2CDK2 | |
| SCHEMBL29412270 | 0.83 | VIPR2 (0.66) | VIPR1VIPR2PTH1RGLP1R | |
| SCHEMBL30980377 | 0.83 | OPRL1 (0.58) | OPRL1CCNA2CDK2CCNA1AGTR2 | |
| SCHEMBL31104935 | 0.82 | GLP1R (0.70) | VIPR1VIPR2PTH1RCCKBRGLP1R | |
| SCHEMBL29389123 | 0.82 | PTH1R (0.63) | VIPR1VIPR2PTH1RGLP1R | |
| SCHEMBL31104924 | 0.82 | GLP1R (0.66) | VIPR1VIPR2PTH1RCCKBRGLP1R | |
| SCHEMBL30122771 | 0.82 | CCNA2 (0.64) | CCNA2CDK2CCNA1AGTR1AGTR2 | |
| SCHEMBL30974467 | 0.81 | OPRL1 (0.55) | OPRL1VIPR1VIPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107405-A2 | COMPOSITIONS AND METHODS FOR ENHANCED CNS DELIVERY THROUGH A NOVEL PROTEIN INTERACTION | SANGAMO THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| WO-2025098503-A1 | CEREBLON E3 UBIQUITIN LIGASE INHIBITOR | 甘李药业股份有限公司 | 2025-05-15 | — | — | WO | claimed |
| WO-2024240268-A1 | CEREBELLAR PROTEIN E3 UBIQUITIN LIGASE INHIBITOR AND CHIMERIC COMPOUND TARGETING PROTEIN DEGRADATION | 甘李药业股份有限公司 | 2024-11-28 | — | — | WO | claimed |
| CN-115141179-B | Novel benzoheterocyclyl derivative, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2024-09-13 | — | — | CN | claimed |
| CN-118480030-A | Cerebulin ligands and bifunctional compounds comprising same | 阿尔维纳斯运营股份有限公司 | 2024-08-13 | — | — | CN | claimed |
| WO-2024156294-A1 | ESTROGEN RECEPTOR PROTEOLYSIS TARGETING CHIMERA COMPOUND AND USE THEREOF | 甘李药业股份有限公司 | 2024-08-02 | — | — | WO | claimed |
| CN-117279910-A | Modulators of BCL6 proteolysis and related methods of use | 阿尔维纳斯运营股份有限公司 | 2023-12-22 | — | — | CN | claimed |
| WO-2023143589-A1 | CEREBLON E3 UBIQUITIN LIGASE INHIBITOR | 甘李药业股份有限公司 | 2023-08-03 | — | — | WO | claimed |
| WO-2023143494-A1 | NEW PROTAC COMPOUND | 甘李药业股份有限公司 | 2023-08-03 | — | — | WO | claimed |
| CN-115397460-A | Methods of making cells expressing chimeric antigen receptors | 诺华股份有限公司 | 2022-11-25 | — | — | CN | claimed |
| CN-115246821-A | Multikinase degradants | 休斯敦大学系统 | 2022-10-28 | — | — | CN | claimed |
| CN-115210381-A | Detection of novel degradation-related interactions | 奥里尼斯生物科学股份有限公司 | 2022-10-18 | — | — | CN | claimed |
| CN-114650989-A | Multikinase degradation agents | 休斯敦大学系统 | 2022-06-21 | — | — | CN | claimed |
| WO-2026107405-A2 | COMPOSITIONS AND METHODS FOR ENHANCED CNS DELIVERY THROUGH A NOVEL PROTEIN INTERACTION | SANGAMO THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260029409-A1 | MARKERS FOR DIAGNOSING INFECTIONS | MEMED DIAGNOSTICS LTD. (IL) | 2026-01-29 | — | — | US | disclosed |
| WO-2025122565-A1 | TARGETING THE G 4C 2 REPEAT-CONTAINING RNA WITH A HIGH-FIDELITY CRISPR-CAS13 SYSTEM IMPROVES ABNORMALITIES ASSOCIATED WITH ALS/FTD | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2025-06-12 | — | — | WO | disclosed |
| CN-114096565-A | PIP4K inhibits insulin signaling and enhances immune function through a non-catalytic dependent mechanism | 康奈尔大学 | 2022-02-25 | — | — | CN | disclosed |
| EP-3615689-B1 | ANALYTICAL METHODS AND ARRAYS FOR USE IN THE SAME | SENZAGEN AB (SE) | 2022-02-23 | — | — | EP | disclosed |
| CN-108474752-B | System and method for detecting syringe seal defects | W.L.戈尔及同仁股份有限公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-113957103-A | Method for producing methacrylic acid and/or ester thereof | 三菱化学株式会社 | 2022-01-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260029409-A1 | MARKERS FOR DIAGNOSING INFECTIONS | AGER, TSG101, ST14 | OPRL1 2530/4885VIPR1 555/4885VIPR2 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.